Suzanne Jenkins

4.0k total citations · 2 hit papers
31 papers, 2.4k citations indexed

About

Suzanne Jenkins is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Suzanne Jenkins has authored 31 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 12 papers in Oncology and 9 papers in Molecular Biology. Recurrent topics in Suzanne Jenkins's work include Lung Cancer Treatments and Mutations (13 papers), Cancer Genomics and Diagnostics (9 papers) and Colorectal Cancer Treatments and Studies (5 papers). Suzanne Jenkins is often cited by papers focused on Lung Cancer Treatments and Mutations (13 papers), Cancer Genomics and Diagnostics (9 papers) and Colorectal Cancer Treatments and Studies (5 papers). Suzanne Jenkins collaborates with scholars based in United Kingdom, United States and Taiwan. Suzanne Jenkins's co-authors include Heather J. Cordell, James Copeman, June Davies, John A. Todd, Peter Reed, Sheila Palmer, Mireille Cantarini, Stephen Gough, Yoshihiko Kawaguchi and Anthony Barnett and has published in prestigious journals such as Nature, Journal of Biological Chemistry and Nature Genetics.

In The Last Decade

Suzanne Jenkins

31 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A genome-wide search for human type 1 diabetes susceptibility genes

1994 964 citations June Davies, Yoshihiko Kawaguchi et al. Nature profile →
EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291

2015 401 citations Kenneth S. Thress, Roz Brant et al. Lung Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Suzanne Jenkins United Kingdom	17	984	751	705	622	574	31	2.4k
Michele Rubini Italy	25	841 0.9×	1.7k 2.3×	272 0.4×	535 0.9×	664 1.2×	76	3.3k
Juha Saharinen Finland	25	717 0.7×	1.9k 2.6×	338 0.5×	404 0.6×	473 0.8×	34	3.0k
Anna Savoia Italy	38	778 0.8×	1.7k 2.3×	737 1.0×	332 0.5×	231 0.4×	121	4.1k
Mary Shago Canada	21	613 0.6×	1.4k 1.8×	353 0.5×	183 0.3×	397 0.7×	57	2.3k
Evgenia Pak United States	23	445 0.5×	2.4k 3.2×	258 0.4×	279 0.4×	331 0.6×	42	3.3k
Eevi Kaasinen Finland	24	303 0.3×	1.6k 2.1×	289 0.4×	318 0.5×	314 0.5×	49	3.4k
Tadasuke Tsukiyama Japan	24	420 0.4×	1.7k 2.3×	277 0.4×	284 0.5×	500 0.9×	36	2.5k
Maria Grazia Tibiletti Italy	29	503 0.5×	838 1.1×	212 0.3×	469 0.8×	812 1.4×	93	2.3k
Axel A. Thomson United Kingdom	25	501 0.5×	1.1k 1.4×	729 1.0×	201 0.3×	227 0.4×	40	2.1k
Gianfranco Sebastio Italy	31	1.0k 1.1×	1.6k 2.1×	211 0.3×	267 0.4×	128 0.2×	82	3.4k

Countries citing papers authored by Suzanne Jenkins

Since Specialization

Citations

This map shows the geographic impact of Suzanne Jenkins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suzanne Jenkins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suzanne Jenkins more than expected).

Fields of papers citing papers by Suzanne Jenkins

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Suzanne Jenkins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suzanne Jenkins. The network helps show where Suzanne Jenkins may publish in the future.

Co-authorship network of co-authors of Suzanne Jenkins

This figure shows the co-authorship network connecting the top 25 collaborators of Suzanne Jenkins. A scholar is included among the top collaborators of Suzanne Jenkins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Suzanne Jenkins. Suzanne Jenkins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Falchook, Gerald S., Jasgit C. Sachdev, Sanjeev Kumar, et al.. (2023). A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors. Investigational New Drugs. 41(3). 493–502. 17 indexed citations

Bauer, Todd M., Kathleen N. Moore, Janet S. Rader, et al.. (2023). A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors. Targeted Oncology. 18(4). 517–530. 21 indexed citations

John, Thomas, Hiroaki Akamatsu, Angelo Delmonte, et al.. (2018). EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer. Lung Cancer. 126. 133–138. 35 indexed citations

Jenkins, Suzanne, James Chih‐Hsin Yang, Suresh S. Ramalingam, et al.. (2017). Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non–Small Cell Lung Cancer. Journal of Thoracic Oncology. 12(7). 1061–1070. 221 indexed citations

Akamatsu, Hiroaki, Angelo Delmonte, Thomas John, et al.. (2017). EGFR mutation analysis for prospective patient (pt) selection in AURA3 Phase III trial of osimertinib vs platinum-pemetrexed (plt-pem) in pts with EGFR T790M positive advanced non-small cell lung cancer (NSCLC). Annals of Oncology. 28. x128–x128. 5 indexed citations

Jenkins, Suzanne, James Chih‐Hsin Yang, Pasi A. Jänne, et al.. (2017). EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib. Journal of Thoracic Oncology. 12(8). 1247–1256. 46 indexed citations

Wu, Yi‐Long, Suzanne Jenkins, Suresh S. Ramalingam, et al.. (2017). MA08.03 Osimertinib vs Platinum-Pemetrexed for T790M-Mutation Positive Advanced NSCLC (AURA3): Plasma ctDNA Analysis. Journal of Thoracic Oncology. 12(1). S386–S386. 22 indexed citations

Jenkins, Suzanne, James Chih‐Hsin Yang, Sundar Ramalingam, et al.. (2016). 134O_PR: Plasma ctDNA analysis for detection of EGFR T790M mutation in patients (pts) with EGFR mutation-positive advanced non-small cell lung cancer (aNSCLC). Journal of Thoracic Oncology. 11(4). S153–S154. 16 indexed citations

Thress, Kenneth S., Roz Brant, T. Hedley Carr, et al.. (2015). EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer. 90(3). 509–515. 401 indexed citations breakdown →

10.

Bhattacharyya, Sumit, Jian’an Luan, Benjamin Challis, et al.. (2006). Sequence variants in the melatonin-related receptor gene (GPR50) associate with circulating triglyceride and HDL levels. Journal of Lipid Research. 47(4). 761–766. 34 indexed citations

11.

Spriewald, Bernd M., Stephan Ensminger, Suzanne Jenkins, Peter J. Morris, & Kathryn J. Wood. (2004). Intrathymic delivery of plasmid-encoding endoplasmic reticulum signal-sequence-deleted MHC class�I alloantigen can induce long-term allograft survival. Transplant International. 17(8). 458–462. 2 indexed citations

12.

Spriewald, Bernd M., Stephan Ensminger, Suzanne Jenkins, Peter J. Morris, & Kathryn J. Wood. (2004). Intrathymic delivery of plasmid-encoding endoplasmic reticulum signal-sequence-deleted MHC class I alloantigen can induce long-term allograft survival. Transplant International. 17(8). 458–462. 1 indexed citations

13.

Babovic‐Vuksanovic, Dusica, et al.. (2003). Subtelomeric deletion of 18p in an adult with paranoid schizophrenia and mental retardation. American Journal of Medical Genetics Part A. 124A(3). 318–322. 23 indexed citations

14.

Jenkins, Suzanne & Neil Gibson. (2002). High‐throughput SNP genotyping. Comparative and Functional Genomics. 3(1). 57–66. 56 indexed citations

15.

Mustafa, Zehra, Marilyn S. Rugg, Brian D. Marsden, et al.. (2002). A Novel Allelic Variant of the Human TSG-6 Gene Encoding an Amino Acid Difference in the CUB Module. Journal of Biological Chemistry. 277(18). 15354–15362. 51 indexed citations

16.

Jenkins, Suzanne, Ruth March, R. Duncan Campbell, & Caroline M. Milner. (2000). A novel variant of the MHC‐linked hsp70, hsp70‐hom, is associated with rheumatoid arthritis. Tissue Antigens. 56(1). 38–44. 22 indexed citations

17.

Spriewald, Bernd M., Masaki Hara, Andrew Bushell, et al.. (2000). Differential Role for Competitive Reverse Transcriptase-Polymerase Chain Reaction and Intracellular Cytokine Staining as Diagnostic Tools for the Assessment of Intragraft Cytokine Profiles in Rejecting and Nonrejecting Heart Allografts. American Journal Of Pathology. 157(5). 1453–1458. 12 indexed citations

18.

Vasey, P., Neil A. Jones, Suzanne Jenkins, Caroline Dive, & Robert Brown. (1996). Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance.. Molecular Pharmacology. 50(6). 1536–1540. 96 indexed citations

19.

Davies, June, James Copeman, Heather J. Cordell, et al.. (1995). LINKAGE MAPPING OF TYPE-1 DIABETES. The American Journal of Human Genetics. 57. 1–1. 72 indexed citations

20.

Davies, June, Yoshihiko Kawaguchi, Simon T. Bennett, et al.. (1994). A genome-wide search for human type 1 diabetes susceptibility genes. Nature. 371(6493). 130–136. 964 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact